Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Pineau, Christian A
Hanly, John G
Urowitz, Murray B
Clarke, Ann E
Wallace, Daniel J
Merrill, Joan T
Isenberg, David A
Ginzler, Ellen M
Dooley, Mary Anne
Gladman, Dafna D
Khamashta, Munther A
Zoma, Asad A
van Vollenhoven, Ronald F
Kalunian, Kenneth C
Kamen, Diane L
Peschken, Christine A
Bruce, Ian N
MetadataShow full item record
CitationUse of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. 2019, 58(7):1259-1267 Rheumatology (Oxford)
AbstractOBJECTIVES: To assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications. METHODS: This observational cohort study included premenopausal women ages 18-45 years enrolled in the SLICC Registry ⩽15 months after SLE onset, with annual assessments spanning 2000-2017. World Health Organization Category 3 or 4 contraindications to CHCs (e.g. hypertension, aPL) were assessed at each study visit. High disease activity (SLEDAI score >12 or use of >0.5 mg/kg/day of prednisone) was considered a relative contraindication. RESULTS: A total of 927 SLE women contributed 6315 visits, of which 3811 (60%) occurred in the presence of one or more possible contraindication to CHCs. Women used CHCs during 512 (8%) visits, of which 281 (55%) took place in the setting of one or more possible contraindication. The most frequently observed contraindications were aPL (52%), hypertension (34%) and migraine with aura (22%). Women with one or more contraindication were slightly less likely to be taking CHCs [7% of visits (95% CI 7, 8)] than women with no contraindications [9% (95% CI 8, 10)]. CONCLUSION: CHC use was low compared with general population estimates (>35%) and more than half of CHC users had at least one possible contraindication. Many yet unmeasured factors, including patient preferences, may have contributed to these observations. Further work should also aim to clarify outcomes associated with this exposure.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
- Combined hormonal contraception use in reproductive-age women with contraindications to estrogen use.
- Authors: Lauring JR, Lehman EB, Deimling TA, Legro RS, Chuang CH
- Issue date: 2016 Sep
- Medical contraindications in women seeking combined hormonal contraception.
- Authors: Xu H, Eisenberg DL, Madden T, Secura GM, Peipert JF
- Issue date: 2014 Mar
- Impact of UK Medical Eligibility Criteria implementation on prescribing of combined hormonal contraceptives.
- Authors: Briggs PE, Praet CA, Humphreys SC, Zhao C
- Issue date: 2013 Jul
- Side effects unrelated to disease activity and acceptability of highly effective contraceptive methods in women with systemic lupus erythematosus: a randomized, clinical trial.
- Authors: Cravioto MD, Jiménez-Santana L, Mayorga J, Seuc AH
- Issue date: 2014 Aug
- Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke.
- Authors: Champaloux SW, Tepper NK, Monsour M, Curtis KM, Whiteman MK, Marchbanks PA, Jamieson DJ
- Issue date: 2017 May